Medical device company Tryton Medical has received marketing approval in Europe for its novel stent system.
With a CE Mark in hand, Durham-based Tryton aims to begin a commercial launch of its Tryton Side Branch Short Stent. Tryton’s stents are designed to address bifurcation lesions, which occur when plaque has built up at the juncture of a main artery and a side branch. Tryton’s stent system support both the main artery and the side branch. The Tryton Short Stent is 3 mm shorter in the main branch zone than the standard Tryton Side Branch Stent.
Tryton said it would launch its new stent next week in Paris during EuroPCR 2013, the annual meeting of the European Association for Percutaneous Cardiovascular Interventions.
Tryton’s Side Branch Stent is still an investigational device in the United States. The company has completed enrollment in a clinical trial. Data is expected to be ready for presentation in the fall at TCT 2013, the annual meeting of Transcatheter Cardiovascular Therapeutics.
